172 related articles for article (PubMed ID: 38066723)
1. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.
Crassini K; Gibson J
Intern Med J; 2024 Jan; 54(1):16-25. PubMed ID: 38066723
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
Rogers BB
Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
5. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Huang LW; Wong SW; Andreadis C; Olin RL
Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
[TBL] [Abstract][Full Text] [Related]
6. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Hagemeister F
Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive approach to therapy of haematological malignancies in older patients.
Cordoba R; Eyre TA; Klepin HD; Wildes TM; Goede V
Lancet Haematol; 2021 Nov; 8(11):e840-e852. PubMed ID: 34624238
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
10. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
11. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.
Hernández-Molina G; Kostov B; Brito-Zerón P; Vissink A; Mandl T; Hinrichs AC; Quartuccio L; Baldini C; Seror R; Szántó A; Isenberg D; Gerli R; Nordmark G; Rasmussen A; Solans-Laque R; Hofauer B; Sène D; Pasoto SG; Rischmueller M; Praprotnik S; Gheita TA; Danda D; Armağan B; Suzuki Y; Valim V; Devauchelle-Pensec V; Retamozo S; Kvarnstrom M; Sebastian A; Atzeni F; Giacomelli R; Carsons SE; Kwok SK; Nakamura H; Fernandes Moça Trevisani V; Flores-Chávez A; Mariette X; Ramos-Casals M;
Rheumatology (Oxford); 2022 Dec; 62(1):243-255. PubMed ID: 35385104
[TBL] [Abstract][Full Text] [Related]
12. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
[TBL] [Abstract][Full Text] [Related]
13. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
14. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract][Full Text] [Related]
15. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.
Vander Meeren S; Heyrman B; Renmans W; Bakkus M; Maes B; De Raeve H; Schots R; Jochmans K
Ann Hematol; 2018 Jul; 97(7):1219-1227. PubMed ID: 29492600
[TBL] [Abstract][Full Text] [Related]
17. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
18. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
19. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
Alley CL; Wang E; Dunphy CH; Gong JZ; Lu CM; Boswell EL; Burchette J; Lagoo AS
Arch Pathol Lab Med; 2013 Apr; 137(4):503-17. PubMed ID: 23544940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
